Document is current
Any future updates will be listed below
-
Authors
Polistena, Barbara https://orcid.org/0000-0002-0138-0223
Provenzano, Anna Maria
Rizzi, Caterina
Colombo, Elena
Bergamaschi, Roberto
-
Funding
Funding for this research was provided by:
Merck (https://doi.org/10.13039/100009945)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 29 April 2025
First Online: 4 June 2025
Declarations
:
: Anna Maria Provenzano and Caterina Rizzi are employees of Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA. Barbara Polistena received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Eli Lilly, Janssen Cilag, Nestlé HS, Novartis, Novo Nordisk, Pfizer, Servier, Takeda, Teva; in addition she received consulting fees from UCB.
: The data used in the study were from the literature or expert opinion. This study uses a pharmacoeconomic model and therefore the approval of an ethics committee is not necessary.
: Roberto Bergamaschi has received funding for travel, speaker honoraria, research support from Biogen, Bristol Myers, Janssen, Merck, Novartis, Roche, Sanofi. Elena Colombo reports travel expenses, speaker honoraria, advisory board work and research support from Sanofi, Biogen, Novartis, Merck, Roche, Bristol MS, Janssen, Alexion. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
